Clarus Therapeutics shares are trading higher after the company was granted a U.S. Patent titled ‘Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same.’
by | Nov 23, 2021 | Extra Jobs | 0 comments
by | Nov 23, 2021 | Extra Jobs | 0 comments
Recent Comments